Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.

Mucosal vaccination presents a promising complement to parenteral vaccination. Bacterium-like particles (BLPs), peptidoglycan structures prepared from lactic acid bacteria, are explored as potential nasal vaccine adjuvants for respiratory infections. To date, studies on BLP-adjuvanted nasal vaccines against intestinal infections have remained limited.

The adjuvant effect of bacterium-like particles depends on the route of administration.

Direct administration of vaccines to mucosal surfaces, such as oral or nasal vaccination, represents an attractive alternative, or complement, to current parenteral vaccination because it has a potential to induce antigen-specific immunity both at mucosal and systemic tissues. Although bacterium-like particles (BLPs), peptidoglycan structures derived from lactic acid bacteria, have been investigated as a novel adjuvant for oral or nasal vaccines, it remains unclear whether the administration routes differ the adjuvant effect of BLPs. Here, we showed that the adjuvant effect of BLPs from NZ9000 is greater with the nasal administration than with the oral administration.

Thixotropic Supramolecular Gel Based on l-Lysine Derivatives.

The dimer l-lysine derivatives, in which two ,-diacyl-l-lysines were crosslinked by calcium ion, were synthesized through a simply synthetic procedure and their gelation properties were examined. These compounds functioned as an organogelator; especially, the gelators possessing both a linear and a branched alkyl chains had the better organogelation ability and formed the thermally stable and rigid organogel. In addition, some organogels had a thixotropic property, which were responsive to a mechanical stimulus and reversibly underwent the gel⁻sol transition at room temperature.